Results for tag: "Beta Thalassemia Drug"

Beta Thalassemia is a type of inherited blood disorder caused by a mutation in the beta-globin gene. It is characterized by anemia, fatigue, and other symptoms. Treatment for Beta Thalassemia includes blood transfusions, iron chelation therapy, and drugs. Hematological drugs are used to treat a variety of blood disorders, including Beta Thalassemia. These drugs are used to reduce the symptoms of the disorder, improve the quality of life, and reduce the need for blood transfusions. The Beta Thalassemia Drug market is a rapidly growing segment of the Hematological Drugs market. It is driven by the increasing prevalence of the disorder, the development of new drugs, and the increasing demand for better treatments. The market is expected to continue to grow in the coming years, as new drugs are developed and the demand for better treatments increases. Some of the companies in the Beta Thalassemia Drug market include Novartis, GlaxoSmithKline, Pfizer, Sanofi, and Johnson & Johnson. Show Less Read more